



Patented Medicine
Prices Review Board
Canada

Conseil d'examen du prix
des médicaments brevetés
Canada

Box L40, Standard Life Centre
333 Laurier Avenue West
Suite 1400
Ottawa, Ontario
K1P 1C1

PROTECTED

Via Electronic Mail
karen.shaw@cps.sk.ca

March 29, 2022

Dear Dr. Karen Shaw:

RE: Appointment to the Human Drug Advisory Panel (HDAP)

The Patented Medicine Prices Review Board (PMPRB) requests your assistance in identifying suitable candidates for appointment to its Human Drug Advisory Panel (HDAP). We are seeking to fill two vacancies on the Panel.

A key point of the mandate of the PMPRB is to ensure that the prices charged by patentees for patented medicines are not excessive.

In 1990, the PMPRB established the HDAP to assist in the evaluation of the appropriate level of therapeutic improvement of new drug products and the identification of comparable medicines and dosage regimens. The HDAP is comprised of members who are medical or pharmacy practitioners with recognized expertise in drug therapy and who have experience in clinical research methodology, statistical analysis and the evaluation of new drugs. Members of the HDAP have usually had experience on a hospital, provincial or national formulary committee. They are appointed on the basis of their individual expertise and not to represent any interested party. Ordinarily, HDAP members participate in one annual one day face-to-face meeting in Ottawa and three web-based meetings during the year and in the evaluation of drug submissions throughout the year. The time the members commit to the activities of the HDAP approximates 15 to 20 days per year.

The current members of the HDAP are:

- Dr. Adil Virani (Associate Professor, Faculty of Pharmaceutical Sciences UBC and Director, Pharmacy Services Fraser Health Authority);
- Dr. Peter Jamieson, (Medical Director, Foothills Hospital, Associate Zone Medical Director, Calgary for Alberta Health Services and Clinical Professor in the Department of Family Medicine at the University of Calgary);
- Dr. Michael Rieder (Professor with the Department of Paediatrics (with a cross-appointment to the Department of Physiology and Pharmacology) in the Faculty of Medicine and Dentistry at the University of Western Ontario in London and Head of the Division of Paediatric Clinical Pharmacology and Scientist at Robarts Research Institute)
- Dr. Muhammad Mamdani (Vice President of Data Science and Advanced Analytics at Unity Health Toronto and Director of the University of Toronto Temerty Faculty of Medicine Centre for Artificial Intelligence Education and Research in Medicine (T-CAIREM), Professor in the Department of Medicine and Professor in the Department of Health Policy, Management and Evaluation at the University of Toronto.

As mentioned above, we are in the process of recruiting to fill two additional positions for addition to the Panel as soon as possible. Of note, we are specifically seeking candidates with a background in hematology or medical oncology to fill one of the two positions.

We would appreciate receiving your suggestions for names of individuals who would be suitable candidates for the HDAP. In doing so, we ask that you provide a brief rationale for your proposal. Please provide a complete address, telephone number and email address for each nominee and, if readily available, a copy of the nominee's curriculum vitae.

We ask that you submit your suggestions by April 25, 2022, to the undersigned by e-mail at Dianne.breau@pmprb-cepmb.gc.ca .

If you have any questions or require any additional information, you can contact me at (343) 548-2584.

Yours very truly,

Dianne Breau, BSc(Pharm) ACPR PharmD
Chief, Scientific Analysis